You sleep eight hours and wake up exhausted. Your labs come back “normal.” Your doctor suggests exercise. You want to scream. The fatigue that plagues women — especially during perimenopause, postpartum, and chronic illness — isn’t always about sleep. It’s often about what’s happening inside your mitochondria.
Mitochondria are the energy factories in every cell. They convert food into ATP — the molecule your body uses for everything: thinking, moving, healing, even sleeping. When mitochondrial function declines, energy production drops at the cellular level. No amount of caffeine fixes this because caffeine stimulates alertness, not actual energy production.
Mitochondrial function declines with age, hormonal changes (particularly estrogen withdrawal during menopause), chronic inflammation, and oxidative stress. This is why perimenopause-related fatigue often feels qualitatively different from being “tired” — it’s cellular exhaustion.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme required for mitochondrial energy production. By age 50, NAD+ levels have dropped roughly 50% from their peak. Supplemental NAD+ (via IV infusion, subcutaneous injection, or oral precursors like NMN/NR) directly supports mitochondrial function. Many women report noticeable improvements in energy, mental clarity, and exercise tolerance within 1-2 weeks of starting NAD+ therapy.
SS-31 is a tetrapeptide that concentrates in mitochondrial membranes, specifically binding to cardiolipin — a lipid essential for electron transport chain function. It protects mitochondria from oxidative damage and improves energy production efficiency. SS-31 is being studied for mitochondrial diseases and age-related conditions. For women with fatigue that doesn’t respond to conventional approaches, SS-31 targets the organelle where energy is actually made.
MOTS-C is encoded in mitochondrial DNA — it’s literally a signal peptide from your mitochondria. It regulates metabolic homeostasis, improves insulin sensitivity, and enhances cellular energy metabolism. For women with PCOS-related insulin resistance or menopause-related metabolic slowdown, MOTS-C addresses the metabolic foundation of fatigue.
Poor sleep is both a cause and consequence of fatigue. CJC-1295/Ipamorelin enhances natural growth hormone pulses during deep sleep, improving sleep quality while supporting cellular repair processes that happen overnight. Many women report that fixing sleep with a GH secretagogue transforms their daytime energy more than any stimulant ever did.
| Fatigue Type | Primary Peptide | Supporting |
|---|---|---|
| General / cellular fatigue | NAD+ | CJC-1295/Ipa for sleep |
| Perimenopause fatigue | NAD+ + CJC-1295/Ipa | Selank if brain fog |
| PCOS metabolic fatigue | MOTS-C | NAD+ for mitochondrial support |
| Post-illness / chronic fatigue | NAD+ + SS-31 | Thymosin Alpha-1 for immune |
| Postpartum exhaustion | NAD+ (after breastfeeding) | GHK-Cu topical for skin |
NAD+ IV infusion delivers the molecule directly to the bloodstream at high concentrations but requires a clinical visit (typically 2-4 hours) and costs $250-1000+ per session. Subcutaneous NAD+ injection is self-administered, more affordable, and provides sustained levels. Oral NAD+ precursors (NMN, NR) are the most accessible but have lower bioavailability. Many practitioners recommend an initial IV loading phase followed by subcutaneous maintenance.
Many women report noticeable improvements in energy and mental clarity within 1-2 weeks of starting NAD+ therapy. IV infusions often produce same-day effects. The full benefit typically builds over 4-8 weeks as mitochondrial function improves. Results vary based on baseline NAD+ depletion, age, and overall health status.
CFS/ME is a complex condition with multiple proposed mechanisms including mitochondrial dysfunction, immune dysregulation, and neuroinflammation. NAD+ and SS-31 (mitochondrial support) and Thymosin Alpha-1 (immune modulation) are theoretically relevant. However, no peptide has been clinically validated for CFS. Work with a provider experienced in both CFS and peptide therapy.
NAD+ (and its precursors NMN/NR) have been used clinically for several years with a favorable safety profile. Long-term studies specifically on supplemental NAD+ are still ongoing. The theoretical concern is that NAD+ supports energy production in all cells, including potentially cancerous ones, so some practitioners recommend cancer screening before starting. Discuss long-term use with your provider.